Literature DB >> 25601275

NOD mice are functionally deficient in the capacity of cross-presentation.

Chin-Nien Lee1, Andrew M Lew2, Ken Shortman2, Li Wu3.   

Abstract

Cross-presentation by CD8(+) conventional dendritic cells (cDCs) is involved in the maintenance of peripheral tolerance and this process is termed cross-tolerance. Previous reports showed that non-obese diabetic (NOD) mice have reduced number of splenic CD8(+) cDCs compared with non-diabetic strains, and that the administration of Flt3L to enhance DC development resulted in reduced diabetes incidence. As CD8(+) cDCs are the most efficient antigen cross-presenting cells, it was assumed that reduced cross-presentation by non-activated, tolerogenic CD8(+) cDC predisposes to autoimmune diabetogenesis. Here we show for the first time that indeed NOD mice have a defect in autoantigen cross-presentation capacity. First, we showed that NOD CD8(+) cDCs were less sensitive to iatrogenic cytochrome c, which had previously been shown to selectively deplete CD8(+) cDCs that functionally cross-present. Second, we found that proliferation of islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-specific CD8(+) T cells was impaired in NOD compared with non-obese diabetes resistant mice after immunization with cell associated recombinant fusion protein containing the cognate IGRP peptide. This study, therefore, suggests that the reduced number of CD8(+) cDCs in NOD mice, coupled with the reduced capacity to cross-present self-antigens, reduces the overall capacity to maintain peripheral tolerance in the spontaneous autoimmune type 1 diabetes mice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25601275     DOI: 10.1038/icb.2014.119

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  50 in total

1.  Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice.

Authors:  L D Poulton; M J Smyth; C G Hawke; P Silveira; D Shepherd; O V Naidenko; D I Godfrey; A G Baxter
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

2.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

Authors:  A Rodriguez; A Regnault; M Kleijmeer; P Ricciardi-Castagnoli; S Amigorena
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

Review 3.  Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Authors:  William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

4.  Dendritic cells in the thymus contribute to T-regulatory cell induction.

Authors:  Anna I Proietto; Serani van Dommelen; Penghui Zhou; Alexandra Rizzitelli; Angela D'Amico; Raymond J Steptoe; Shalin H Naik; Mireille H Lahoud; Yang Liu; Pan Zheng; Ken Shortman; Li Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

5.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Authors:  Nicholas S Wilson; Dima El-Sukkari; Gabrielle T Belz; Christopher M Smith; Raymond J Steptoe; William R Heath; Ken Shortman; José A Villadangos
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

Review 6.  The potential role of dendritic cells in the therapy of Type 1 diabetes.

Authors:  Chin-Nien Lee; Andrew M Lew; Li Wu
Journal:  Immunotherapy       Date:  2013-06       Impact factor: 4.196

7.  Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer.

Authors:  M J Clare-Salzler; J Brooks; A Chai; K Van Herle; C Anderson
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset.

Authors:  Ming Lee Lin; Yifan Zhan; Anna I Proietto; Sandro Prato; Li Wu; William R Heath; Jose A Villadangos; Andrew M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

9.  Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequences.

Authors:  P Santamaria; T Utsugi; B J Park; N Averill; S Kawazu; J W Yoon
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

10.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  5 in total

Review 1.  The Importance of Dendritic Cells in Maintaining Immune Tolerance.

Authors:  Cindy Audiger; M Jubayer Rahman; Tae Jin Yun; Kristin V Tarbell; Sylvie Lesage
Journal:  J Immunol       Date:  2017-03-15       Impact factor: 5.422

2.  Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.

Authors:  Jennifer Schloss; Riyasat Ali; Jeffrey Babad; Ignacio Guerrero-Ros; Jillamika Pongsachai; Li-Zhen He; Tibor Keler; Teresa P DiLorenzo
Journal:  Immunohorizons       Date:  2019-06-26

Review 3.  Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.

Authors:  Chie Hotta-Iwamura; Kristin V Tarbell
Journal:  J Leukoc Biol       Date:  2016-01-20       Impact factor: 4.962

4.  Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice.

Authors:  Sarah R Leist; Carolin Pilzner; Judith M A van den Brand; Leonie Dengler; Robert Geffers; Thijs Kuiken; Rudi Balling; Heike Kollmus; Klaus Schughart
Journal:  BMC Genomics       Date:  2016-02-27       Impact factor: 3.969

Review 5.  Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?

Authors:  Rémi J Creusot; Jorge Postigo-Fernandez; Nato Teteloshvili
Journal:  Diabetes       Date:  2018-08       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.